Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2012 5
2013 5
2014 8
2015 11
2016 8
2017 10
2018 11
2019 14
2020 17
2021 10
2022 5
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Turoctocog alfa (NovoEight)--from design to clinical proof of concept.
Ezban M, Vad K, Kjalke M. Ezban M, et al. Eur J Haematol. 2014 Nov;93(5):369-76. doi: 10.1111/ejh.12366. Epub 2014 May 28. Eur J Haematol. 2014. PMID: 24797664 Free PMC article. Review.
Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. ...Half-lives of 7.2 0.9 h in F8-KO mice and 8.9 1.8 h haemophilia A dogs supported that turoctocog alfa bound to VWF after inf …
Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. . …
Turoctocog alfa for the treatment of hemophilia a.
Vakil NH, Fujinami N, Martin-Stone S. Vakil NH, et al. Pharmacotherapy. 2014 Oct;34(10):1091-101. doi: 10.1002/phar.1469. Epub 2014 Jul 23. Pharmacotherapy. 2014. PMID: 25052207 Review.
Although turoctocog alfa was approved by the U.S. Food and Drug Administration in 2013, it will not be available on the market until 2015. Turoctocog alfa appears to be a safe and effective alternative to currently available recombinant FVIII concentra …
Although turoctocog alfa was approved by the U.S. Food and Drug Administration in 2013, it will not be available on the market …
Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
Takedani H, Hirose J. Takedani H, et al. Drug Des Devel Ther. 2015 Mar 24;9:1767-72. doi: 10.2147/DDDT.S57967. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25848213 Free PMC article. Review.
Turoctocog alfa is the first B-domain-truncated third generation recombinant coagulation factor VIII (FVIII) product. ...Three clinical trials are ongoing to assess the long-term safety and efficacy of turoctocog alfa for PTPs and previously untreated …
Turoctocog alfa is the first B-domain-truncated third generation recombinant coagulation factor VIII (FVIII) product. ...Three …
Turoctocog Alfa -- Benefit Assessment According to 35a Social Code Book V.
Institute for Quality and Efficiency in Health Care. Institute for Quality and Efficiency in Health Care. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2014 Apr 10. Extract of Dossier Assessment No. A14-04. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2014 Apr 10. Extract of Dossier Assessment No. A14-04. PMID: 27905771 Free Books & Documents. Review.
The aim of the present report is to assess the added benefit of turoctocog alfa compared with the appropriate comparator therapy (ACT) in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). ...
The aim of the present report is to assess the added benefit of turoctocog alfa compared with the appropriate comparator thera …
Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.
Tiede A, Klamroth R, Oldenburg J. Tiede A, et al. Hamostaseologie. 2015;35(4):364-71. doi: 10.5482/HAMO-15-06-0019. Epub 2015 Aug 14. Hamostaseologie. 2015. PMID: 26271775 Review.
Turoctocog alfa (NovoEight) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of tyrosine sulphation, similar to plasma-derived FVIII products. The manufacturing process includes double nanofiltration with a 20-nm pore size and im …
Turoctocog alfa (NovoEight) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of tyrosine …
An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.
Boban A, Hermans C. Boban A, et al. Expert Rev Hematol. 2020 Apr;13(4):303-311. doi: 10.1080/17474086.2020.1740586. Epub 2020 Mar 14. Expert Rev Hematol. 2020. PMID: 32153219 Review.
Advancements in biotechnology have enabled development of recombinant factor concentrates, which thus minimize the risk of transmitting infectious diseases. Turoctocog alfa (NovoEight, Novo Nordisk A/S, Bagsvaerd, Denmark) was the first third-generation B-domain tru …
Advancements in biotechnology have enabled development of recombinant factor concentrates, which thus minimize the risk of transmitting infe …
Turoctocog alfa for the treatment of hemophilia A.
Haddley K. Haddley K. Drugs Today (Barc). 2014 Feb;50(2):121-31. doi: 10.1358/dot.2014.50.2.2116671. Drugs Today (Barc). 2014. PMID: 24619589 Review.
Plasma-derived or synthetic recombinant FVIII is used to control bleeding, but currently available treatments are limited because of patient development of FVIII inhibitors and cross-contamination of human and animal-derived infectious agents. Turoctocog alfa is a r …
Plasma-derived or synthetic recombinant FVIII is used to control bleeding, but currently available treatments are limited because of patient …
Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
Tosetto A, Neff A, Lentz SR, Santagostino E, Nemes L, Sathar J, Meijer K, Chowdary P, Shen C, Landorph A, Hampton K. Tosetto A, et al. Haemophilia. 2020 May;26(3):450-458. doi: 10.1111/hae.13980. Epub 2020 Apr 15. Haemophilia. 2020. PMID: 32293786 Free PMC article. Clinical Trial.
INTRODUCTION: Turoctocog alfa pegol is a glycoPEGylated recombinant factor VIII (FVIII) with an extended half-life developed for prophylaxis, treatment of bleeds and perioperative management in patients with haemophilia A. AIM: Evaluate the efficacy and safety of …
INTRODUCTION: Turoctocog alfa pegol is a glycoPEGylated recombinant factor VIII (FVIII) with an extended half-life developed f …
An overview of turoctocog alfa pegol (N8-GP; ESPEROCT() ) assay performance: Implications for postadministration monitoring.
Ezban M, Hansen M, Kjalke M. Ezban M, et al. Haemophilia. 2020 Jan;26(1):156-163. doi: 10.1111/hae.13897. Epub 2019 Dec 6. Haemophilia. 2020. PMID: 31809565 Free PMC article. Review.
Certain silica-based APTT reagents have previously been shown to underestimate FVIII activity with the polyethylene glycol (PEG)-conjugated product turoctocog alfa pegol (N8-GP [ESPEROCT() ]; Novo Nordisk A/S). As a wide range of assay reagents are used in clinical …
Certain silica-based APTT reagents have previously been shown to underestimate FVIII activity with the polyethylene glycol (PEG)-conjugated …
Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40C.
Napolitano M, Olsen AA, Nøhr AM, Eichler H. Napolitano M, et al. J Blood Med. 2021 Jan 25;12:9-20. doi: 10.2147/JBM.S284060. eCollection 2021. J Blood Med. 2021. PMID: 33536803 Free PMC article.
In addition, turoctocog alfa and turoctocog alfa pegol dry powders were evaluated for stability at 5C/ambient humidity (AH) for 30 months, 30C/75% relative humidity (RH) for 12 months and 40C/75% RH for 6 months. ...CONCLUSION: Turoctocog alf …
In addition, turoctocog alfa and turoctocog alfa pegol dry powders were evaluated for stability at 5C/ambient hu …
97 results